Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Georgia Owen

Nurse Practitioner, Women's Health Columbus, OH Nurse Practitioner

NPI 1730528621 CMS profile 11184911

21 E State St Ste 200, Columbus, OH 43215

Open in the dashboard

General payments

$2,457

119 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Georgia Owen of Columbus, OH is reported in the CMS Open Payments database as having received $2,457 across 119 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner, Women's Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $43 2
2024 General $562 25
2023 General $606 29
2022 General $585 33
2021 General $662 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Georgia Owen
  • Nurse Practitioner, Women's Health median
  • Middle half of Nurse Practitioner, Women's Health
  • National median

In program year 2025, general payments to Georgia Owen were reported at $43. Among 3,829 Nurse Practitioner, Women's Health profiles paid that year, the median was $124 and the middle half received between $42 and $307.

Show as a table
Year Georgia Owen Nurse Practitioner, Women's Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $662 $110 $33–$291 $132
2022 $585 $122 $40–$314 $149
2023 $606 $131 $40–$333 $160
2024 $562 $123 $43–$298 $164
2025 $43 $124 $42–$307 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $693 33 payments
  2. Pfizer Inc. $200 11 payments
  3. Astellas Pharma US Inc $197 8 payments
  4. Sumitomo Pharma America, Inc. $190 10 payments
  5. Myovant Sciences Inc. $184 9 payments
  6. Mayne Pharma Inc. $158 7 payments
  7. Sage Therapeutics, Inc. $136 6 payments
  8. Organon LLC $113 5 payments
  9. Agile Therapeutics, Inc. $90 5 payments
  10. SCYNEXIS, Inc. $63 3 payments
  11. Other $433 22 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,371 117 payments
  2. Education $86 2 payments
Products named General payments · program years 2021–2025
  1. MYFEMBREE Hormone Therapy $374 19 payments
  2. ORIAHNN $296 11 payments
  3. PREMARIN $274 15 payments
  4. LO LOESTRIN FE $238 15 payments
  5. ORILISSA $225 8 payments
  6. MYFEMBREE Genitourinary (Sexual Health);Womens Health $161 9 payments
  7. LILETTA $159 7 payments
  8. ZURZUVAE $136 6 payments
  9. ESTRING $110 6 payments
  10. Veozah $93 5 payments
  11. Other $890 46 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$1,444

Medicare's payments for the services billed

Medicare patients

20

Average age 72

Services billed

23

20 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MYFEMBREE
  • Sumitomo Pharma America, Inc. $46
  • PFIZER INC. $8
$54 — —
Veozah
  • Astellas Pharma US Inc $41
$41 — —
DUAVEE
  • PFIZER INC. $8
$8 — —
PREMARIN
  • PFIZER INC. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record